1. Home
  2. AUGO vs CELC Comparison

AUGO vs CELC Comparison

Compare AUGO & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AUGO

Aura Minerals Inc.

HOLD

Current Price

$60.30

Market Cap

6.0B

Sector

N/A

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$88.82

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUGO
CELC
Founded
1946
2011
Country
United States
United States
Employees
1462
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
7.0B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
AUGO
CELC
Price
$60.30
$88.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
9
Target Price
$67.60
$112.56
AVG Volume (30 Days)
700.8K
1.7M
Earning Date
05-06-2026
05-13-2026
Dividend Yield
1.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$91.05
N/A
Revenue Next Year
$17.09
$720.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.55
$11.54
52 Week High
$110.32
$151.02

Technical Indicators

Market Signals
Indicator
AUGO
CELC
Relative Strength Index (RSI) 38.62 31.63
Support Level $59.30 $83.77
Resistance Level $77.01 $117.61
Average True Range (ATR) 4.07 7.68
MACD -0.96 -3.25
Stochastic Oscillator 29.98 9.24

Price Performance

Historical Comparison
AUGO
CELC

About AUGO Aura Minerals Inc.

Aura Minerals Inc is a mid-tier gold and copper production company focused on the development and operation of gold and base metal projects in the Americas. The company's operating segments include: Minosa Mine, Apoena Mine, the Aranzazu Mine, Almas Mine, Borborema Mine and Serra Grande Mine. It derives maximum revenue from Aranzazu Mine. The company's growth projects include: Matupa in Brazil, and Era Dorada in Guatemala. whereas its exploration projects include: Carajas, in Brazil, and Tolda Fria in Colombia.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: